These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 27965309)

  • 1. Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody.
    Dominguez GA; Condamine T; Mony S; Hashimoto A; Wang F; Liu Q; Forero A; Bendell J; Witt R; Hockstein N; Kumar P; Gabrilovich DI
    Clin Cancer Res; 2017 Jun; 23(12):2942-2950. PubMed ID: 27965309
    [No Abstract]   [Full Text] [Related]  

  • 2. First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.
    Forero A; Bendell JC; Kumar P; Janisch L; Rosen M; Wang Q; Copigneaux C; Desai M; Senaldi G; Maitland ML
    Invest New Drugs; 2017 Jun; 35(3):298-306. PubMed ID: 28050790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
    Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
    Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.
    Condamine T; Kumar V; Ramachandran IR; Youn JI; Celis E; Finnberg N; El-Deiry WS; Winograd R; Vonderheide RH; English NR; Knight SC; Yagita H; McCaffrey JC; Antonia S; Hockstein N; Witt R; Masters G; Bauer T; Gabrilovich DI
    J Clin Invest; 2014 Jun; 124(6):2626-39. PubMed ID: 24789911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
    Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
    Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients.
    Jordan KR; Kapoor P; Spongberg E; Tobin RP; Gao D; Borges VF; McCarter MD
    Cancer Immunol Immunother; 2017 Apr; 66(4):503-513. PubMed ID: 28108766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid-Derived Suppressor Cells.
    Gabrilovich DI
    Cancer Immunol Res; 2017 Jan; 5(1):3-8. PubMed ID: 28052991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Posttransplant Mobilization of Monocytic Myeloid-derived Suppressor Cell Correlates With Increase in Soluble Immunosuppressive Factors and Predicts Cancer in Kidney Recipients.
    Utrero-Rico A; Laguna-Goya R; Cano-Romero F; Chivite-Lacaba M; Gonzalez-Cuadrado C; Rodríguez-Sánchez E; Ruiz-Hurtado G; Serrano A; Fernández-Ruiz M; Justo I; González E; Andrés A; Paz-Artal E
    Transplantation; 2020 Dec; 104(12):2599-2608. PubMed ID: 32068661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditioned media from the renal cell carcinoma cell line 786.O drives human blood monocytes to a monocytic myeloid-derived suppressor cell phenotype.
    Okada SL; Simmons RM; Franke-Welch S; Nguyen TH; Korman AJ; Dillon SR; Gilbertson DG
    Cell Immunol; 2018 Jan; 323():49-58. PubMed ID: 29103587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
    Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
    Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells.
    Zhou J; Yao Y; Shen Q; Li G; Hu L; Zhang X
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1371-1380. PubMed ID: 28321548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of T cells by myeloid-derived suppressor cells in cancer.
    Chen J; Ye Y; Liu P; Yu W; Wei F; Li H; Yu J
    Hum Immunol; 2017 Feb; 78(2):113-119. PubMed ID: 27939507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease.
    Netherby CS; Abrams SI
    Cancer Immunol Immunother; 2017 Aug; 66(8):989-996. PubMed ID: 28224211
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Burvenich IJ; Lee FT; Guo N; Gan HK; Rigopoulos A; Parslow AC; O'Keefe GJ; Gong SJ; Tochon-Danguy H; Rudd SE; Donnelly PS; Kotsuma M; Ohtsuka T; Senaldi G; Scott AM
    Theranostics; 2016; 6(12):2225-2234. PubMed ID: 27924159
    [No Abstract]   [Full Text] [Related]  

  • 15. Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function.
    Stiff A; Trikha P; Mundy-Bosse B; McMichael E; Mace TA; Benner B; Kendra K; Campbell A; Gautam S; Abood D; Landi I; Hsu V; Duggan M; Wesolowski R; Old M; Howard JH; Yu L; Stasik N; Olencki T; Muthusamy N; Tridandapani S; Byrd JC; Caligiuri M; Carson WE
    Clin Cancer Res; 2018 Apr; 24(8):1891-1904. PubMed ID: 29363526
    [No Abstract]   [Full Text] [Related]  

  • 16. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
    Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
    MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation.
    Speigl L; Burow H; Bailur JK; Janssen N; Walter CB; Pawelec G; Shipp C
    Breast Cancer Res Treat; 2018 Apr; 168(2):401-411. PubMed ID: 29230664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production.
    Netherby CS; Messmer MN; Burkard-Mandel L; Colligan S; Miller A; Cortes Gomez E; Wang J; Nemeth MJ; Abrams SI
    J Immunol; 2017 May; 198(10):4129-4139. PubMed ID: 28356386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients.
    Tobin RP; Davis D; Jordan KR; McCarter MD
    J Leukoc Biol; 2017 Aug; 102(2):381-391. PubMed ID: 28179538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer.
    Ko HJ; Kim YJ
    Arch Pharm Res; 2016 Nov; 39(11):1597-1608. PubMed ID: 27572156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.